Internal Medicine, Hematology & Oncology · Tigard, OR
NPI
1376546309
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
12123 SW 69th Ave
Tigard, OR, 97223
Phone (971) 708-7600
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
80,066 services
Medicare patients, 2024
366
Average age 74
Drug cost, 2024
$2.2M
640 prescriptions
Company payments, 2024
$15
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Edward H Chang was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 12,750 times for 19 patients. In total Edward H Chang billed 80,066 services in 163 codes, and Medicare paid $1.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-17.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 12,750 | 19 | $0.28 | $3,508 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 11,100 | 17 | $2.35 | $26K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 8,201 | 18 | $44.65 | $366K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 3,820 | 36 | $0.10 | $391 |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,516 | 11 | $0.08 | $278 |
| J0185 Injection, aprepitant, 1 mg | Office | 3,380 | 20 | $1.34 | $4,538 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 2,100 | 11 | $0.11 | $238 |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 1,860 | 12 | $48.94 | $91K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 701 | 43 | $0.09 | $63.08 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 530 | 26 | $0.25 | $131 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 450 | 33 | $0.73 | $326 |
| 85025 Blood Count | Office | 377 | 124 | $7.59 | $2,863 |
| 80053 Clinical Chemistry | Office | 360 | 123 | $10.33 | $3,718 |
| 36415 Venipuncture Blood Collection | Office | 349 | 121 | $8.63 | $3,010 |
| Q5122 Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 240 | 11 | $59.72 | $14K |
By year: 2022 $1.3M for 118,723 services; 2023 $1.0M for 80,739 services; 2024 $1.2M for 80,066 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 377 | 124 | $7.59 | $2,863 |
| 80053 Clinical Chemistry | 360 | 123 | $10.33 | $3,718 |
| 36415 Venipuncture Blood Collection | 349 | 121 | $8.63 | $3,010 |
| 83540 Clinical Chemistry | 150 | 70 | $6.31 | $946 |
| 83550 Clinical Chemistry | 150 | 70 | $8.52 | $1,279 |
| 82728 Clinical Chemistry | 149 | 70 | $13.29 | $1,980 |
| 83883 Clinical Chemistry | 70 | 14 | $13.33 | $933 |
| 82378 Clinical Chemistry | 47 | 14 | $18.58 | $873 |
| 83615 Clinical Chemistry | 25 | 18 | $5.92 | $148 |
Medicare prescription drug claims, 2024
In 2024, the drug Edward H Chang prescribed most often to Medicare patients was Hydroxyurea, with 71 prescriptions and refills. In total Edward H Chang wrote 640 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 71 | 146 | 14 | $1,898 |
| Eliquis Apixaban | 62 | 100 | 17 | $57K |
| Acyclovir Generic | 31 | 34 | Under 11 | $368 |
| Dexamethasone Generic | 29 | 30 | 11 | $483 |
| Lenalidomide Generic | 26 | 26 | Under 11 | $330K |
| Imatinib Mesylate Generic | 26 | 26 | Under 11 | $20K |
| Calquence Acalabrutinib Maleate | 24 | 24 | Under 11 | $349K |
| Allopurinol Generic | 22 | 44 | Under 11 | $441 |
| Tamoxifen Citrate Generic | 19 | 33 | Under 11 | $380 |
| Lorazepam Generic | 18 | 19 | Under 11 | $76.44 |
| Orserdu Elacestrant Hcl | 15 | 15 | Under 11 | $365K |
| Folic Acid Generic | 15 | 24 | Under 11 | $47.73 |
| Revlimid Lenalidomide | 14 | 14 | Under 11 | $332K |
| Jakafi Ruxolitinib Phosphate | 13 | 13 | Under 11 | $218K |
| Anastrozole Generic | 13 | 39 | Under 11 | $173 |
Brand drugs: 189 claims; generic drugs: 451 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Edward H Chang $15 ($15 in general payments such as food, travel and fees) from 1 company. The largest payer was Aveo Pharmaceuticals, Inc. with $15.
| Company | Payments | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. | 1 | $15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.